The median progression-free survival was 32.6 months on the Blenrep combo compared to 12.5 months on the alternative. While ...

"GSK remains confident in the benefit/risk profile of Blenrep and will continue to work closely with the FDA as they complete their review for Blenrep in patients with relapsed or refractory multiple ...

The British pharmaceutical company said combinations for its Blenrep drug were evaluated in adults with relapsed or ...

The Japanese Ministry of Health, Labour and Welfare (MHLW) has granted approval for the use of GSK’s Blenrep (belantamab mafodotin) combinations to treat adults with relapsed or refractory ...

GSK plc announced the approval of Blenrep combinations by Japan’s Ministry of Health, Labour and Welfare (MHLW) for the treatment of adults with relapsed or refractory multiple myeloma. The approval ...

A Japan expansion cohort is set to further evaluate the DREAMM-8 protocol in Japanese patients. Results for Japanese participants will be presented at a future scientific meeting. About Blenrep ...

A Japan expansion cohort is set to further evaluate the DREAMM-8 protocol in Japanese patients. Results for Japanese participants will be presented at a future scientific meeting. Blenrep is an ...

Japan approves GSK’s Blenrep combinations for multiple myeloma treatment ...

Investing.com -- GSK plc (LON: GSK), a U.K.-based pharmaceutical company, said on Monday that its Blenrep combinations have been approved by Japan’s Ministry of Health. This approval is for the ...